Dimension Therapeutics, Inc. DMTX
Set alert
At close · Jun 28
- Open
- 5.98
- Prev close
- 5.95
- Mkt cap
- 149.97M
- Vol
- 27.70K
- Avg vol
- 92.06K
- EPS
- -2.13
- P/E
- -2.79
- Div yield
- 0.00%
More statistics
- Low
- 5.95
- High
- 6.00
- Forward P/E
- -2.70
- Beta
- 0.00
- Short ratio
- 4.13
- Inst. own
- 71.22%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 6, 2017
- 50-d avg
- 25.72
- 200-d avg
- 8.79
- 1y target
- 6.00
Key statistics
- Market cap
- 149.97M
- Enterprise value
- 108.60M
- Trailing P/E
- -2.79
- Forward P/E
- -2.70
- PEG ratio
- 0.00
- Price / sales
- 10.08
- Price / book
- 4.13
- EPS (TTM)
- -2.13
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 14.88M
- Revenue growth
- 84.30%
- Free cash flow
- -32.19M
- Total cash
- 47.49M
- Total debt
- 5.78M
- Return on equity
- -87.64%
- Shares outstanding
- 25.21M
- Short % of float
- 1.17%
- 50-day average
- 25.72
- 200-day average
- 8.79
Analyst view
Consensus: hold
Next earnings
Nov 6, 2017
Expected Nov 6, 2017. Consensus EPS estimate -0.48.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2017 | Sep 1, 2017 | -0.49 | — | — | — |
| Aug 8, 2017 | Jun 1, 2017 | -0.49 | — | — | — |
| May 10, 2017 | Mar 1, 2017 | -0.49 | — | — | — |
| Mar 9, 2017 | Dec 1, 2016 | -0.54 | — | — | — |
| Nov 10, 2016 | Sep 1, 2016 | -0.51 | — | — | — |
| Aug 11, 2016 | Jun 1, 2016 | -0.45 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 2017 | Wells Fargo | down | Outperform | Market Perform |
| Oct 2, 2017 | Citigroup | up | Sell | Neutral |
| Sep 18, 2017 | Citigroup | down | Neutral | Sell |
| Aug 29, 2017 | Canaccord Genuity | down | Buy | Hold |
| May 11, 2017 | Citigroup | down | — | Neutral |
| Jan 31, 2017 | Cantor Fitzgerald | down | — | Neutral |
About Dimension Therapeutics, Inc.
Dimension Therapeutics, Inc., a gene therapy platform company, focuses on discovering and developing therapeutic products for people living with rare and metabolic diseases associated with the liver. The company's pipeline of programs includes DTX101, a lead gene therapy product candidate designed to deliver FIX gene expression in patients with hemophilia B; and DTX201, a FVIII gene therapy program for the treatment of hemophilia A. Its pipeline programs also comprise DTX301, a gene therapy product candidate for the treatment of ornithine transcarbamylase deficiency; DTX401, a gene therapy program for the treatment of glycogen storage disease type Ia; DTX501, gene therapy program for the treatment of patients with PKU; DTX701, a gene therapy program for the treatment of Wilson disease; and DTX601, a gene therapy program for the treatment of citrullinemia type I. Dimension Therapeutics, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
- Country
- United States
- Website
- dimensiontx.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on DMTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CLARK K. REED | Officer | Option Exercise | Jun 6, 2016 | 0 |
| FMR LLC | Other | Disposition (Non Open Market) | Nov 6, 2017 | 0 |
| WADSWORTH SAMUEL C. | Officer | Disposition (Non Open Market) | Nov 6, 2017 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Orbimed Advisors LLC. | 21.27% | 5,397,698 | 32.39M | Sep 29, 2017 |
| FMR, LLC | 19.29% | 4,893,322 | 29.36M | Sep 29, 2017 |
| New Leaf Venture Partners, L.L.C. | 8.12% | 2,059,283 | 12.36M | Sep 29, 2017 |
| FIL LTD | 6.66% | 1,688,870 | 10.13M | Sep 29, 2017 |
| Baker Brothers Advisors, LLC | 4.93% | 1,251,881 | 7.51M | Sep 29, 2017 |
| Vanguard Group, Inc. (The) | 2.41% | 610,285 | 3.66M | Sep 29, 2017 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1.17% | 296,385 | 459.40K | Jun 29, 2017 |
| Vanguard Total Stock Market Index Fund | 0.76% | 192,659 | 298.62K | Jun 29, 2017 |
| Fidelity Extended Market Index Fund | 0.31% | 78,948 | 106.58K | Jul 30, 2017 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.20% | 50,800 | 78.74K | Jun 29, 2017 |
| College Retirement Equities Fund-Stock Account | 0.16% | 41,249 | 72.19K | Mar 30, 2017 |
| iShares Micro Cap ETF | 0.13% | 32,744 | 98.23K | Aug 30, 2017 |